BioWorld

June 29, 2004

Amgen's GDNF Misses In Phase II Parkinson's Trial

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. (BioWorld Today) Read More

Virogenomics New Spin-Off Artielle: $11M For MS Work

Alteon's Stock Sale Raises Up To $12.8M For Phase IIs

LSBC, University Of Louisville Join Up To Develop HPV Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...